Group 1 - The stock price of the biopharmaceutical company,药捷安康-B (2617.HK), surged by 53% to reach 295 HKD, setting a new record since its IPO, with a market capitalization exceeding 110 billion HKD [1] - Since its listing on June 23, the stock price has increased over 21 times from the IPO price of 13.15 HKD within less than three months [1] - The company focuses on discovering and developing innovative small molecule therapies for oncology, inflammation, and cardiovascular metabolic diseases, with its core product, Tinengotinib, being a unique MTK inhibitor in the registration clinical stage [1] Group 2 - On September 10, the company announced that its core product, Tinengotinib, in combination with Fulvestrant, received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial targeting hormone receptor-positive (HR+) and HER2-negative or low-expressing recurrent or metastatic breast cancer, which is set to be completed by September 10, 2025 [1]
港股异动丨药捷安康上市不到3个月飙升超21倍，市值升破1100亿港元
Sou Hu Cai Jing·2025-09-15 05:47